On 18th April, the "Zhangjiang in Action - Finance Supports the Biomedical Innovation Research and Development Conference" was successfully held in Zhangjiang Science City, hosted by the Shanghai Promotion Office for Scientific and Technological Innovation (Shanghai Sci-Tech Innovation Center). Shanghai FTZ Fund, as a representative of the Pudong New Area's sci-tech investment institutions, participated in the conference.

According to the Shanghai Sci-Tech Innovation Center, in 2022, Shanghai had 4 Category I innovative drugs approved for market launch, ranking first nationwide, and 9 Category III innovative medical devices approved, ranking second nationwide. In the first quarter of 2023, Shanghai has already approved 3 Category I innovative drugs, maintaining its first-place position nationwide. 

By the first quarter of 2023, there are a total of 79 domestic and overseas listed companies in the field of biomedicine in Zhangjiang Science City, accounting for 82% of the total in Shanghai. The total market value is 1,160.8 billion yuan, accounting for 87% of the total in Shanghai. Among them, there are 24 companies listed on the Science and Technology Innovation Board (STAR Market) in Zhangjiang Biomedical Industry, accounting for 89% of the total in Shanghai. The total market value is 381 billion yuan, accounting for 95% of the total in Shanghai.

Zhangjiang Science City is an important area for Shanghai's sci-tech industries and a gathering place for high-quality projects that Shanghai FTZ Fund is committed to deepening. The fund has a deep understanding of the strategic and investment opportunities of Pudong, led by Zhangjiang Science City and Lingang Special Area, in building a modern and new industrial system, especially in the "future industries". The fund focuses on the "dual focus" strategy of the free trade zone and sci-tech innovation, accelerating its layout in the segmented tracks of the "future health", "future chips", "future intelligence", "future new energy & materials", and other sub-sectors by investing in growth and core technologies. At the same time, the fund continues to implement a systematic empowerment investment philosophy, providing companies with integration of resources in the industrial chain, collaborative services between industries, and continuous investment and financing services.